文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

有丝分裂活动指数和 CD25+ 淋巴细胞可预测非肌肉浸润性膀胱癌的分期进展风险。

Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.

机构信息

Department of Pathology, Stavanger University Hospital, Stavanger, Norway.

Department of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway.

出版信息

PLoS One. 2020 Jun 2;15(6):e0233676. doi: 10.1371/journal.pone.0233676. eCollection 2020.


DOI:10.1371/journal.pone.0233676
PMID:32484812
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7266352/
Abstract

In urothelial cell type non-muscle invasive urinary bladder carcinoma, TNM stage and WHO grade are widely used to classify patients into low and high‑risk groups for prognostic and therapeutic decision-making. However, stage and grade reproducibility and prediction accuracy are wanting. This may lead to suboptimal treatment. We evaluated whether proliferation features, nuclear area of the epithelial cancer cells and the composition of stromal and tumor infiltrating lymphocytes have independent prognostic value. In 183 primary non-muscle invasive bladder cancer patients with long follow-up (median for stage progression cohort: 119 months, range 5-173; median for tumor recurrence cohort: 82, range 3-165) proliferation features Ki67, PPH3 and Mitotic Activity Index (MAI), Mean Nuclear Area (MNA), lymphocyte subsets (CD8+, CD4+, CD25+) and plasma cells (CD138+) were assessed on consecutive sections. Post-resection instillation treatments (none, mitomycin, BCG) were strictly standardized during the intake period. Risk of recurrence was associated with expression of Ki67 (≤ 39 vs. > 39) and Multifocality (p = 0.01). Patients with low Ki67 had a higher recurrence rate than those with high Ki67. Lymphocyte composition did not predict recurrence. Stage progression was strongly associated with high values for MAI (>15) and CD25+ (>0.2%). In a multivariate analysis the combination of MAI and CD25+ was the single most prognostic feature (p<0.001). Validation of these results in additional, independent studies is warranted.

摘要

在尿路上皮细胞型非肌肉浸润性膀胱癌中,TNM 分期和 WHO 分级广泛用于将患者分为低风险和高风险组,以进行预后和治疗决策。然而,分期和分级的可重复性和预测准确性并不理想。这可能导致治疗不当。我们评估了增殖特征、上皮癌细胞的核面积以及基质和肿瘤浸润淋巴细胞的组成是否具有独立的预后价值。在 183 例具有长期随访的原发性非肌肉浸润性膀胱癌患者中(进展队列的分期中位数:119 个月,范围 5-173;肿瘤复发队列的中位数:82 个月,范围 3-165),在连续切片上评估了增殖标志物 Ki67、PPH3 和有丝分裂活动指数(MAI)、平均核面积(MNA)、淋巴细胞亚群(CD8+、CD4+、CD25+)和浆细胞(CD138+)。在纳入期严格标准化了术后膀胱灌注治疗(无治疗、丝裂霉素、BCG)。复发风险与 Ki67 的表达(≤39 与>39)和多灶性(p=0.01)相关。Ki67 低表达的患者比 Ki67 高表达的患者有更高的复发率。淋巴细胞组成与复发无关。进展期与高 MAI(>15)和 CD25+(>0.2%)值密切相关。在多变量分析中,MAI 和 CD25+的组合是唯一最具预后特征的因素(p<0.001)。需要在其他独立研究中验证这些结果。

相似文献

[1]
Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.

PLoS One. 2020-6-2

[2]
Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.

Hum Pathol. 2014-3-26

[3]
CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.

J Urol. 2015-3-6

[4]
Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.

J Cancer Res Ther. 2021

[5]
Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder.

Urology. 2002-12

[6]
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.

J Urol. 2017-5-6

[7]
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.

Future Oncol. 2021-8

[8]
Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.

J Clin Pathol. 2003-6

[9]
Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.

Eur Urol. 2000-9

[10]
Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.

Urol Oncol. 2012-4-21

引用本文的文献

[1]
Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer.

Diagnostics (Basel). 2024-9-26

[2]
Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy.

Int J Mol Sci. 2024-4-27

[3]
Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.

PLoS One. 2024-1-26

[4]
Non-muscle invasive bladder cancer biomarkers beyond morphology.

Front Oncol. 2022-8-3

[5]
"How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.

Front Oncol. 2021-12-21

本文引用的文献

[1]
Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas.

Diagn Pathol. 2019-8-14

[2]
Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.

Sci Rep. 2018-5-10

[3]
Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.

Clin Cancer Res. 2018-1-24

[4]
Significance of Ki-67 in non-muscle invasive bladder cancer patients: a systematic review and meta-analysis.

Oncotarget. 2017-10-13

[5]
Implications of the tumor immune microenvironment for staging and therapeutics.

Mod Pathol. 2017-12-1

[6]
Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy.

PeerJ. 2017-10-13

[7]
Epidemiology of urothelial carcinoma.

Int J Urol. 2017-10

[8]
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.

Eur Urol. 2017-4-28

[9]
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Oncotarget. 2016-6-28

[10]
Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence.

Oncotarget. 2016-2-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索